Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The University of Virginia /Padova Type 1 Diabetes (TID) simulator has been widely used for testing artificial pancreas controllers, and, recently, novel insulin formulations and glucose sensors. However, a module describing the pharmacokinetics of the new long-acting insulin analogues is not available. The aim of this contribution is to reproduce multiple daily insulin injection (MDI) therapy, with insulin glargine 100 U/mL (Gla-100) as basal insulin, using the TID simulator. This was achieved by developing a model of Gla-100 and by incorporating it into the simulator. The methodology described here can be extended to other insulins, allowing an extensive in silico testing of different long-acting insulin analogues under various settings before starting human trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“models of acetaminophen pharmacokinetic and long-acting insulin were introduced; [74][75][76]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [75]
Citations
Cites
Meal Simulation Model of the Glucose-Insulin System
Dalla Man, C., Rizza, R. A., & Cobelli, C. (2007) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2007.893506 · Cited by 955 · cited 2×
“In particular, VI has been fixed to population values, while m2, m3, m4 have been derived from m1, the plasma insulin clearance (CL, L/min), body weight (BW, kg) and VI, accordingly with [8]:”
BackgroundMethodSelf-citationThe UVA/PADOVA Type 1 Diabetes Simulator: New Features
Man, C. D., Micheletto, F., Lv, D., Breton, M., Kovatchev, B., & Cobelli, C. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813514502 · Cited by 791 · cited 3×
“Plasma insulin kinetic is described by the twocompartment model already implemented in the UVA/Padova T1D simulator [3]:”
BackgroundMethodSelf-citationIn Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes
Kovatchev, B. P., Breton, M., Dalla Man, C., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300106 · Cited by 760 · cited 1×
“In particular, thanks to its ability to reproduce glucose variability characterizing the T1D population [2],[3], the University of Virginia (UVA) and Padova T1D Simulator has been widely used to test artificial pancreas algorithms and, recently, glucose sensors and novel insulin formulations [4].”
BackgroundSelf-citationBecker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 1×
“NCT01349855) [7], a 36-h euglycemic clamp procedure was performed in 30 T1D subjects after 8 days of once-daily sc administrations of Gla-100, 0.”
MethodThe UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day
Visentin, R., Campos-Náñez, E., Schiavon, M., Lv, D., Vettoretti, M., Breton, M., Kovatchev, B. P., Dalla Man, C., & Cobelli, C. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818757747 · Cited by 280 · cited 3×
“The latest version of the simulator [5] incorporates a number of novelties, the most noteworthy represented by a model of diurnal glucose variability, mainly due to the intra-day varations of insulin sensitivity (SI) and the dawn phenomenon, which extended the domain of validity of the simulator from single- to multip…”
BackgroundMethodSelf-citationA minimal model of insulin secretion and kinetics to assess hepatic insulin extraction
Toffolo, G., Campioni, M., Basu, R., Rizza, R. A., & Cobelli, C. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00473.2004 · Cited by 142 · cited 1×
“A priori information was considered for parameters m1 and CL, using the available information [8]; insulin measurement error was assumed independent, Gaussian, with zero mean and known variance [10].”
MethodSelf-citationVisentin, R., Dalla Man, C., Kovatchev, B., & Cobelli, C. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0377 · Cited by 103
Self-citationShiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12415 · Cited by 95 · cited 1×
“NCT01195454) [6], a 36-h euglycemic clamp was performed in 24 T1D subjects receiving a single sc dose of Gla-100, 0.”
MethodModeling Subcutaneous Absorption of Fast-Acting Insulin in Type 1 Diabetes
Schiavon, M., Dalla Man, C., & Cobelli, C. (2018) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2784101 · Cited by 54
Self-citationVisentin, R., Giegerich, C., Jäger, R., Dahmen, R., Boss, A., Grant, M., Dalla Man, C., Cobelli, C., & Klabunde, T. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0128 · Cited by 36
Self-citation
Research works printed but not linked: 1
- 2016, version 9 1 0 441655 (R2016b)
Cited by
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Self-citationCescon, M., Deshpande, S., Nimri, R., Doyle, F. J., & Dassau, E. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.3005622 · Cited by 22
“76 [min], whereas in comparison, in [23], [32], the insulin peak of 22.”
BackgroundMethodResultInfluentialGanji, M., Fathi, A. E., Fabris, C., Lv, D., Kovatchev, B. P., & Breton, M. D. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109714 · Cited by 6
“The UVA/Padova T1D simulator, a simulation platform accepted by the U.S. Food and Drug Administration (FDA), has been utilized for years as a substitute for animal pre-clinical trials, opening new possibilities for designing personalized treatments[20], [21], [22], [23], [24], [25].”
MethodCescon, M., Deshpande, S., Doyle, F., & Dassau, E. (2019) · American Control Conference · doi:10.23919/acc.2019.8814817 · Cited by 4
“developed a pharmacokinetic model of insulin glargine 100 U/mL and incorporated it into the UVa/Padova metabolic simulator [19].”
MethodSiket, M., Toth, R., Szász, L., Novák, K., Eigner, G., & Kovács, L. (2023) · IEEE World Symposium on Applied Machine Intelligence and Informatics (SAMI) · doi:10.1109/sami58000.2023.10044485 · Cited by 3
Metadata
- Authors
- Visentin, R., Schiavon, M., Giegerich, C., Klabunde, T., Man, C. D., & Cobelli, C.
- Affiliations
- University of Padua (IT)
- Sanofi (Germany) (DE)
- ORCID
- Venue
- 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
- Publisher
- IEEE
- Published
- 2018-07
- Volume
- 2018
- Pages
- 4905-4908
- ISSN
- 2375-7477 (ISSN-L)
- OpenAlex
- W2899371333
- Cited by
- 9
- References
- 12
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2020: 2 · 2019: 1
- FWCI
- 4.01
- Type
- conference paper
- Language
- en
- Open access
- closed
- Locations
- Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- long-acting insulin, insulin glargine, type 1 diabetes, in silico clinical trials, insulin pharmacokinetics, basal insulin, multiple daily insulin injections, insulin analogues
- MeSH terms
- Insulin Glargine, Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Insulin, Pancreas, Artificial, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator. https://app.cochat.ai/papers/10.1109/embc.2018.8513234
- The paper
- Visentin, R., Schiavon, M., Giegerich, C., Klabunde, T., Man, C. D., & Cobelli, C. (2018). Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator. 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). https://doi.org/10.1109/embc.2018.8513234
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.